Ligand Pharmaceuticals Revises FY23 Revenue Outlook From $124M-$128M To $124M-$126M; Est. $127.05M
Portfolio Pulse from Benzinga Newsdesk
Ligand Pharmaceuticals has revised its FY23 revenue outlook from $124M-$128M to $124M-$126M, slightly below the estimated $127.05M.
September 18, 2023 | 9:24 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Ligand Pharmaceuticals has lowered its FY23 revenue outlook, which is now below the estimated $127.05M.
Ligand Pharmaceuticals has revised its FY23 revenue outlook downwards. This could potentially indicate that the company is expecting lower sales or facing challenges, which could negatively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100